Searched over 200M research papers for "artery stent"
10 papers analyzed
Some studies suggest that stents are effective in treating various arterial conditions, including aneurysms, ischemic heart disease, and femoropopliteal lesions, while other studies highlight complications such as stent fractures, subclinical ischemic lesions, and limited efficacy in certain conditions like renal function impairment.
19 papers analyzed
Flow-diverting stents (FDSs) are specialized devices designed to treat arterial aneurysms by reducing blood flow velocity within the aneurysm sac, promoting thrombosis, and maintaining flow in the main artery and branch vessels. Common FDSs include the Pipeline Embolization Device, SILK Arterial Reconstruction Device, and Cardiatis Multilayer Stent. These stents have shown promising results in treating extracranial arterial aneurysms, with a high rate of aneurysm thrombosis and volume reduction, and no branch vessel occlusion reported. However, there is a significant incidence of FDS thrombosis, and further investigation is needed for their use in aortic aneurysms.
Carotid artery stenting (CAS) is a procedure used to treat carotid artery stenosis, which can lead to stroke. The design of the stent plays a crucial role in the outcomes of CAS. Studies have shown that while short-term major adverse event (MAE) rates are similar for open cell and closed cell stents, open cell stents are associated with a higher incidence of postprocedural new ischemic lesions. Double-layer stents (DLSs) have been developed to minimize plaque prolapse and embolization, showing a low 30-day stroke rate and rare acute occlusion, making them a promising option for CAS .
Coronary artery stents are widely used in the treatment of ischaemic heart disease (IHD) to widen arteries and improve blood flow. Studies comparing stents with percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft (CABG) have shown that stents are effective in reducing the need for repeat revascularization procedures. Sirolimus-eluting stents (SES) have demonstrated comparable safety to CABG and superior outcomes to bare-metal stents (BMS) over a five-year period, although stent thrombosis remains a concern.
Renal artery stenting is used to treat atherosclerotic renal artery stenosis (ARAS) in patients with impaired renal function. However, studies have shown that stent placement does not significantly affect the progression of renal impairment and is associated with procedure-related complications. Therefore, a conservative approach focusing on cardiovascular risk management is recommended.
In the treatment of long femoropopliteal artery lesions, heparin-bonded covered stents have shown higher efficacy compared to bare-metal stents (BMS), particularly in lesions longer than 20 cm. Covered stents have demonstrated better patency rates and clinical outcomes, making them a preferable option for complex femoropopliteal artery disease. However, stent fractures, particularly in the superficial femoral artery, remain a concern and are associated with higher risks of restenosis and re-occlusion.
Artery stents play a critical role in the treatment of various vascular conditions, including arterial aneurysms, carotid artery stenosis, ischaemic heart disease, renal artery stenosis, and femoropopliteal artery disease. The design and type of stent significantly influence clinical outcomes, with newer technologies like flow-diverting stents and double-layer stents showing promising results. However, complications such as stent thrombosis and fractures highlight the need for ongoing research and careful patient selection to optimize treatment outcomes.
Most relevant research papers on this topic